In-Licensing and Out-Licensing in the Pharmaceutical Industry
Evaluating and Conducting Due Diligence of Product and Licensing Partner; Negotiating and Structuring Term Sheet and Agreements
Recording of a 90-minute premium CLE video webinar with Q&A
This CLE webinar will guide IP counsel on in-licensing and out-licensing in the pharmaceutical industry. The panel will discuss the advantages and disadvantages of both as well as the key considerations when weighing whether to use either type. The panel will also address the evaluation of the product and licensing partner and the due diligence process. The panel will offer best practices for structuring the agreement.
Outline
- Advantages of in-licensing
- Advantages of out-licensing
- Key considerations
- Licensor
- Licensee
- Product and licensing partners
- Evaluation
- Due diligence
- Term sheets
- Structuring licensing agreements
Benefits
The panel will review these and other key issues:
- What key considerations should pharma organizations and counsel weigh when determining whether to in- or out-license technology or products?
- What steps can licensee counsel take to effectively build protections into the license itself?
- What steps should licensor counsel take to mitigate the risks of licensing its technology?
Faculty
Eyal H. Barash
Member
Barash Law
Mr. Barash specializes in legal services for emerging knowledge-based companies with a special emphasis in life science... | Read More
Mr. Barash specializes in legal services for emerging knowledge-based companies with a special emphasis in life science companies. He has a particular focus in counseling companies in solid form patent applications including cocrystals, polymorphs, amorphous dispersions, and salts including prosecution, licensing, and litigation strategies.
Close
Thomas L. Irving
Partner
The Marbury Law Group
Mr. Irving has 47 years of experience in the field of IP law. His practice includes due diligence, patent prosecution,... | Read More
Mr. Irving has 47 years of experience in the field of IP law. His practice includes due diligence, patent prosecution, reissue and reexamination, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement and validity analysis in the chemical fields, as well as litigation. He has served as lead counsel in many patent interferences.
Close
Michelle E. O'Brien
Partner, Head of Life Sciences
The Marbury Law Group
Ms. O’Brien has more than 20 years of experience representing domestic and foreign clients of all sizes in... | Read More
Ms. O’Brien has more than 20 years of experience representing domestic and foreign clients of all sizes in patent procurement, litigation, and client counseling, with a particular emphasis on chemical, biochemical, and pharmaceutical technologies. Exemplary areas of her technical expertise include polymer chemistry; ceramics; glass; food chemistry; cosmetics; paper products; adhesives; and pharmaceutical products, including new chemical entities and formulations and novel solid forms, including polymorphs, cocrystals, and amorphous forms of compounds.
Close